Results 241 to 250 of about 3,877,321 (353)

Market discipline in life insurance: Does public risk disclosure encourage less risky management actions?

open access: yesJournal of Risk and Insurance, Volume 92, Issue 4, Page 909-949, December 2025.
Abstract We analyze how public risk disclosure, specifically Solvency II, impacts life insurers' risk‐taking behavior. Using data from 58 German life insurers from 2016 to 2023, we find that publicly reported solvency ratios can affect premium growth and surrender rates.
Moritz Hanika
wiley   +1 more source

Virtuous innovation or obfuscation? Product innovation in the variable annuities market

open access: yesJournal of Risk and Insurance, Volume 92, Issue 4, Page 978-1012, December 2025.
Abstract Variable Annuities, which comprise a substantial proportion of the retirement products sold by insurance companies, have become increasingly complex over the past decades. We investigate the drivers of the product trends. We distinguish “virtuous” innovations that expand upon the existing set of consumption paths in retirement from ...
Xiaochen Jing   +2 more
wiley   +1 more source

Smooth backfitting for additive hazard rates

open access: yesScandinavian Journal of Statistics, Volume 52, Issue 4, Page 1625-1669, December 2025.
Abstract Smooth backfitting was first introduced in an additive regression setting via a direct projection alternative to the classic backfitting method by Buja, Hastie, and Tibshirani. This paper translates the original smooth backfitting concept to a survival model considering an additively structured hazard.
Stephan M. Bischofberger   +3 more
wiley   +1 more source

Correction: A new asymmetric extended family: Properties and estimation methods with actuarial applications. [PDF]

open access: yesPLoS One
Aljohani HM   +5 more
europepmc   +1 more source

Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians

open access: yesCA: A Cancer Journal for Clinicians, Volume 75, Issue 6, Page 498-527, November/December 2025.
Abstract Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the third leading cause of cancer‐related death worldwide. Contemporary advances in systemic and locoregional therapies have led to changes in peer‐reviewed guidelines regarding systemic therapy as well as the possibility of downstaging disease that may enable some patients
Dimitrios Moris   +12 more
wiley   +1 more source

Amyloid-negative neuropsychological norms: Added value in the era of biomarkers and disease-modifying therapies. [PDF]

open access: yesAlzheimers Dement (Amst)
Rubio-Guerra S   +29 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy